Rituximab for Remission Induction in a Patient with Relapsing Necrotizing Scleritis Associated with Limited Wegener's Granulomatosis
Overview
Authors
Affiliations
Purpose: The authors report a case of necrotizing scleritis associated with Wegener's granulomatosis (WG), which was treated with rituximab for relapsing disease.
Method: Observational case report.
Results: A 32-year-old male patient presented with necrotizing scleritis in his left eye. The patient was diagnosed as having limited WG. Cyclophosphamide was begun. Under maintenance treatment with azathioprine two relapses of scleritis occurred. Since a high cumulative dose of cyclophosphamide (22.5 g) was utilized initially, two intravenous infusions of rituximab 1 g was given. Complete resolution of scleritis occurred.
Conclusions: Rituximab may be effective to induce remission in patients with scleritis due to WG.
Yavari N, Ghoraba H, Mohammadi S, Feky D, Karaca I, Nguyen Q J Ophthalmic Inflamm Infect. 2025; 15(1):26.
PMID: 40080288 PMC: 11906944. DOI: 10.1186/s12348-025-00475-9.
Hajishah H, Amini M, Chadeganipour A, Salehi S, Kazemi D Curr Rheumatol Rev. 2023; 20(3):270-283.
PMID: 37907486 DOI: 10.2174/0115733971263964231020072640.
A Review of Systemic Biologics and Local Immunosuppressive Medications in Uveitis.
Mehta N, Emami-Naeini P J Ophthalmic Vis Res. 2022; 17(2):276-289.
PMID: 35765634 PMC: 9185190. DOI: 10.18502/jovr.v17i2.10804.
Sota J, Girolamo M, Frediani B, Tosi G, Cantarini L, Fabiani C Ophthalmol Ther. 2021; 10(4):777-813.
PMID: 34476773 PMC: 8589879. DOI: 10.1007/s40123-021-00393-8.
Rituximab for non-infectious Uveitis and Scleritis.
Ng C, Sy A, Cunningham Jr E J Ophthalmic Inflamm Infect. 2021; 11(1):23.
PMID: 34396463 PMC: 8364894. DOI: 10.1186/s12348-021-00252-4.